Logo

Dermavant Reports Results of Tapinarof in P-III (PSOARING 3) Study for the Treatment of Plaque Psoriasis

Share this

Dermavant Reports Results of Tapinarof in P-III (PSOARING 3) Study for the Treatment of Plaque Psoriasis

Shots:

  • The P-III (PSOARING 3) extension study evaluates tapinarof (qd) in adult patients with PsO. The results were presented at Winter Clinical Dermatology 2022
  • The results demonstrated high rates of satisfaction across all evaluated parameters. Additionally, 78.5% (n=599) of patients who completed the survey showed that 81.7% considering more effective, 85.8% can manage psoriasis with tapinarof, 82.5% will continue to use tapinarof if available
  • The US FDA has accepted an application for tapinarof to treat PsO in Aug 2021 & assigned a PDUFA date in Q2’22. Tapinarof is a steroid-free, cosmetically elegant topical cream & a therapeutic aryl hydrocarbon receptor modulating agent for PsO & AD

Ref: Businesswire | Image: 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions